{"schema_version":"secwatch.filing_event.v1","accession":"0001558370-23-004866","form_type":"8-K","ticker":"CBIO","cik":"0001253689","company_name":"CRESCENT BIOPHARMA, INC.","filed_at":"2023-03-29T23:59:59+00:00","discovered_at":"2026-05-14T18:03:44.142844+00:00","generated_at":"2026-06-17T10:03:27.278188+00:00","sec_items":["2.02","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"GlycoMimetics reports $47.9M cash; Phase 3 uproleselan trial continues to final events in H1 2024","bullets":["Cash and equivalents $47.9M at Dec 31, 2022; raised $28.7M net from ATM in Q1 2023.","R&D expenses fell to $5.9M in Q4 2022 from $12.9M in Q4 2021; full-year R&D $28.4M vs $47.5M.","DMC recommended Phase 3 uproleselan trial continue after interim utility analysis; final OS events expected H1 2024.","Appointed Edwin Rock as CMO, Bruce Johnson as CCO, and Chinmaya Rath as CBO in 2022-2023.","Cash runway projected to fund operations to end of 2024."],"urls":{"canonical":"https://secwatch.observer/filing/0001558370-23-004866","json":"https://secwatch.observer/filing/0001558370-23-004866.json","markdown":"https://secwatch.observer/filing/0001558370-23-004866.md","text":"https://secwatch.observer/filing/0001558370-23-004866.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1253689/000155837023004866/0001558370-23-004866-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1253689/000155837023004866/glyc-20230329x8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-17T10:03:27.278188+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"8c33ed8121b52599a893d643fcfab39f69a2efae","claim":"CRESCENT BIOPHARMA, INC. reported financial results for quarter and year ended December 31, 2022.","evidence_excerpt":"GlycoMimetics, Inc. (Nasdaq: GLYC) a late clinical-stage biotechnology company discovering and developing glycobiology-based therapies for cancers and inflammatory diseases, today reported its financial results and highlights for the quarter and year ended December 31, 2022.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1253689/000155837023004866/0001558370-23-004866-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"quarter and year ended December 31, 2022"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}